Mladsi, Deirdre
Zhou, Xiaolei
Mader, Gregory
Sanon, Myrlene
Wang, Jinyi
Barnett, Christine
Willey, Cynthia
Seliger, Stephen
Funding for this research was provided by:
Otsuka Pharmaceutical Development and Commercialization
Article History
Received: 8 November 2022
Accepted: 25 January 2024
First Online: 16 February 2024
Declarations
:
: This analysis used deidentified data acquired from a national data system and accordingly received a “not human research” determination from the RTI Institutional Review Board (Federalwide Assurance Number 3331). The present study used secondary data which is available in public domain. The dataset has no identifiable information of the survey participants. All methods are carried out in relevant guidelines and regulations.
: Not applicable.
: DM, XZ, JW, and CB are full time employees of RTI Health Solutions, an independent nonprofit research organization, which was retained by Otsuka to conduct the research that is the subject of this manuscript. Their compensation is unconnected to the studies on which they work. GM was an employee of RTI Health Solutions at the time the research was conducted. MS was an employee of Otsuka at the time the research was conducted. CW has served as an epidemiologic consultant to Otsuka Pharmaceuticals, Inc. SS is an employee of the University of Maryland School of Medicine.